Gastrointestinal neuroectodermal tumor (GNET) : a case.

Tumor neuroectodérmico gastrointestinal maligno (GNET) : a propósito de un caso.

Published 2016-03-01

Open | Download
PDF (Spanish) FLIP
Issue
Vol. 3 No. 1 (2016): Marzo
Section
Clinic cases
How to Cite
Gastrointestinal neuroectodermal tumor (GNET) : a case.
Rev. colomb. hematol. oncol. [Internet]. 2016 Mar. 1 [cited 2024 Dec. 22];3(1):38-41. Disponible en: https://doi.org/10.51643/22562915.148
DOI

https://doi.org/10.51643/22562915.148
Dimensions
PlumX
license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Diego Mauricio González Ramírez
Asociación Colombiana de Hematología y Oncología
    Juan Carlos Velásquez
    Asociación Colombiana de Hematología y Oncología
      Yenni Andrea Quevedo Morales
      Asociación Colombiana de Hematología y Oncología
        Carlos Eduardo Bonilla
        Asociación Colombiana de Hematología y Oncología
          Ricardo Elías Bruges
          Asociación Colombiana de Hematología y Oncología
            Show authors biography

            The gastrointestinal neuroectodermal tumor malignant (GNET) is an extremely rare entity recently described in the literature and is also known as tumor-like clear cell sarcoma of the gastrointestinal tract (CCSLGT) for their morphological and molecular similarity clear cell sarcoma of tendons and aponeuroses (CCS). However, given the presence of rearrangements of EWSR1 gene and neuroectodermal differentiation, some authors has been considered GNET more appropriate term. It is a disease with poor prognosis and high recurrence rate almost always metastatic from diagnosis in contrast to the relatively indolent behavior of CSS. To our knowledge there are fewer than 50 reported cases of this disease and to date this would be the first case located in primary liver and prolonged relapse-free survival after appropriate surgical management and adjuvant chemotherapy

            Article visits 232 | PDF visits 418

            1. Zambrano E, Reyes-Mugica M, Franchi A, Rosai J. An osteoclastrich tumor of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: reports of 6 cases of a GIST simulator. Int J Surg Pathol. 2003;11(2):75-81.
            2. Alpers CE, Beckstead JH. Malignant neuroendocrine tumor of the jejunum with osteoclast-like giant cells. Enzyme histochemistry distinguishes tumor cells from giant cells. Am J Surg Pathol. 1985;9(1):57-64.
            3. Stockman DL, Miettinen M, Suster S, Spagnolo D, DomínguezMalagon H, Hornick JL, et al. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Am J Surg Pathol. 2012;36(6):857-68.
            4. Antonescu CR, Nafa K, Segal NH, Dal Cin P, Ladanyl M. EWSCREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res. 2006;12(18):5356-62.
            5. Balkaransingh P, Saad SA, Govil SC, Thind PK, Balance CM, Weiss AR. Clear cell sarcoma of the gastrointestinal tract presenting as a second malignant neoplasm following neuroblastoma in infancy. Pediatr Blood Cancer. 2012;58(3):481-2.
            6. Donner LR, Trompler RA, Dobin S. Clear cell sarcoma of the ileum: the crucial role of cytogenetics for the diagnosis. Am J Surg Pathol. 1998;22(1):121-4.
            7. Pauwels P, Debiec-Rychter M, Sciot R, Vlasveld T, den Butter B, Hagemeijer A, et al. Clear cell sarcoma of the stomach. Histopathology. 2002;41(6):526-30.
            8. Bridge JA, Borek DA, Neff JR, Huntrakoon M. Chromosomal abnormalities in clear cell sarcoma. Implications for histogenesis. Am J Clin Pathol. 1990;93(1):26-31.
            9. Zafar SF, Patil DH, Kauh JS, Adsay V, Kooby DA, Brutcher E, et al. Neuroendocrine tumors (NET) of the gastrointestinal tract: experience at Winship Cancer Institute of Emory University. J Clin Oncol. 2012;30(15).
            10. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33(9):1401-8.
            11. Zhang Q, Wang H, Ren L, Qi X, Liu F, Zhang D. Primary synovial sarcoma of the prostate metastatic to the liver and lung: a case report. World J Surg Oncol. 2014;12:194.
            12. Srivastava A, Nielsen PG, Dal Cin P, Rosenberg AE. Monophasic synovial sarcoma of the liver. Arch Pathol Lab Med. 2005;129(8):1047-9.
            13. Holla P, Hafez GR, Slukvin I, Kalayoglu M. Synovial sarcoma, a primary liver tumor--a case report. Pathol Res Pract. 2006;202(5):385-7.
            14. Makhlouf HR, Ahrens W, Agarwal B, Dow N, Marshalleck JJ, Lee EL, et al. Synovial sarcoma of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 10 cases. Am J Surg Pathol. 2008;32(2):275-81.
            15. Donner LR, Trompler RA, Dovin S. Clear cell sarcoma of the ileum: the crucial role of cytogenetics for the diagnosis. Am J Surg Pathol. 1998;22(1):121-4.
            16. Abdulkader I, Cameselle-Tejeiro J, de Alava E, Ruiz-Ponte C, Used-Aznar MM, Forteza J. Intestinal clear cell sarcoma with melanocytic differentiation and EWS [corrected] rearrangement: report of a case. Int J Surg Pathol. 2008;16(2):189-93.
            17. Suárez-Vilela D, Izquierdo FM, Tojo-Ramallo S, Riera-Velasco JR, Escobar-Stein J. Malignant gastrointestinal neuroectodermal tumor showing overlapped immunophenotype with synovial sarcoma: CD99 and SOX10 antibodies are useful in differential diagnosis. Am J Surg Pathol. 2012;36(12):1905-8.
            18. Guillou LW, Kraus MD, Dei Tos AP, Fletcher CD. S-100 protein reactivity in synovial sarcomas--a potentially frequent diagnostic pitfall. Immunohistochemical analysis of 100 cases. Appl Immunohistochem Mol Morphol. 1996;4:167-75.
            19. Pauwels P, Debiec-Rychter M, Sciot R, Vlasveld T, den Butter B, Hagemeijer A, et al. Clear cell sarcoma of the stomach. Histopathology. 2002;41(6):526-30.
            20. Antonescu CR, Nafa K, Segal NH, Dal Cin P, Ladanyi M. EWSCREB1: a recurrent variant fusion in clear cell sarcoma--association with gastrointestinal location and absence of melanocytic differentiation. Clin Cancer Res 2006;12(18):5356-62.
            21. Thway K, Judson I, Fisher C. Clear cell sarcoma-like tumor of the gastrointestinal tract, presenting as a second malignancy after childhood hepatoblastoma. Case Rep Med 2014;2014:984369.
            22. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010;70(2):639-45.
            23. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 2012;118(23):5894-902.
            24. http://clinicaltrials.gov/ct2/show/NCT01524926

            Information

            Directories and indexers
            Google Scholar profile

            QR code

            Keywords

            Most read in the last 30 days

            Current Issue

            Sistema OJS 3.4.0.7 - Metabiblioteca |